SB-332235

SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist, with an IC50 of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells[1][2].

Product Specifications

CAS Number

[276702-15-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CXCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sb-332235.html

Purity

98.7

Solubility

10 mM in DMSO

Smiles

O=S(C1=C(Cl)C=CC(NC(NC2=CC=CC(Cl)=C2Cl)=O)=C1O)(N)=O

Molecular Formula

C13H10Cl3N3O4S

Molecular Weight

410.66

Precautions

H302, H315, H319, H335

References & Citations

[1]Podolin PL, et al. A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol. 2002;169 (11) :6435-6444.|[2]Schinke C, et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells [published correction appears in Blood. 2015 Jul 16;126 (3) :425. Barreryo, Laura [corrected to Barreyro, Laura]]. Blood. 2015;125 (20) :3144-3152.